Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1, single ascending dose (SAD), safety study of PGN-EDO51 for the treatment of Duchenne muscular dystrophy (DMD)

Next Previous
X
Search
Trial Profile

A Phase 1, single ascending dose (SAD), safety study of PGN-EDO51 for the treatment of Duchenne muscular dystrophy (DMD)

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 04 Sep 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs PGN-EDO51 (Primary)
  • Indications Duchenne muscular dystrophy
  • Focus Adverse reactions; First in man

    • Most Recent Events

    • 01 Sep 2023 According to a Pepgen Corporation media release, positive results from this trial will be presented at the 2023 Ottawa Neuromuscular Disease Meeting.
    • 27 Apr 2023 Results presented at the 75th Annual Meeting of the American Academy of Neurology 2023
    • 23 Mar 2023 According to a Pepgen Corporation media release, data from this study will be presented at the American Academy of Neurology 2023 Annual Meeting.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top